Immunic Therapeutics
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company.
Launch date
Employees
Market cap
-
Enterprise valuation
$44—66m (Dealroom.co estimates Sep 2017.)
New York City New York (HQ), Munich Bavaria (founding location)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | €17.5m | Series A | |
| N/A | €4.0m | Series A | |
* | €10.0m | Series A | |
| N/A | N/A | - | |
* | €654k | Grant | |
* | $200m | Private Placement VC | |
| Total Funding | $235m | ||